Generic for opsumit?

Is Opsumit currently sold as a generic?
No. Opsumit is an investigational monoclonal antibody still in clinical trials, and it has not yet received FDA approval. Because it is not approved, no generic or biosimilar version exists.

What exactly is Opsumit and what does it target?
Opsumit is a humanized IgG1 monoclonal antibody that blocks the B7‑H3 (CD276) protein, an immune checkpoint that cancer cells use to evade attack. The drug is being studied in patients with metastatic melanoma and other solid tumours to see if it can stimulate the immune system against cancer cells.

Why can’t a generic be offered yet?
Generic versions of biologics are called biosimilars. To develop a biosimilar, the original product must first be licensed, and the company holding the patent must have granted a licence or the patent must have expired. Opsumit’s patents are still active, and the drug has not received regulatory approval, so no biosimilar pathway can be pursued at this time.

When might a generic or biosimilar appear?
The first step is FDA approval of Opsumit. If approval is granted, the drug will likely enter the market within 12‑18 months. Biosimilars usually come after a period of exclusivity—often five to seven years—though the exact timeline depends on patent expirations and regulatory filings. Thus, a generic could appear only several years after first approval.

How can patients access Opsumit today?
Patients can only receive Opsumit through the clinical trials listed on ClinicalTrials.gov (e.g., NCT02589288). These trials enroll patients under strict eligibility criteria and are conducted by research institutions or the sponsor company. If you meet the trial criteria, you can contact the trial team for enrollment details.

Are there other drugs that work on the same target?
Other agents that block B7‑H3 are still in early development and are not yet approved. For patients seeking checkpoint‑inhibitor therapy, FDA‑approved options include PD‑1/PD‑L1 inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda). These drugs have a broader approval history and may be available through standard oncology practices.

How can you verify a drug’s generic status?
Check the FDA’s “Drugs@FDA” database or the European Medicines Agency (EMA) “EudraCT” portal. Both list approved products and indicate whether a biosimilar exists. For investigational agents, consult the FDA’s “ClinicalTrials.gov” database or the company’s website for the latest status updates.

What should I do if I’m looking for a cheaper option?
Since Opsumit is not yet available, consider established checkpoint inhibitors that have generic or biosimilar versions on the market, such as generic pembrolizumab or biosimilar nivolumab, after confirming coverage and eligibility with your healthcare provider.

---

Sources

[1] FDA Center for Biologics Evaluation and Research – Opsumit approval status
[2] ClinicalTrials.gov – NCT02589288, Opsumit trial for metastatic melanoma
[3] ImmunoX Therapeutics – Opsumit product page and development updates